Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide for p53-Mutated Intractable Cancer
NCT04695223Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in solid tumor, sponsored by Shanghai Changzheng Hospital. Primary endpoints: Objective Response Rate at 2 months and Progression Free Survival at 2 months. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04695223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695223.